Boliven Patents - US7037716: Packaging systems for human recombinant adenovirus to be used in gene therapy

Join
today

Boliven PRO is more than just patent search

Build and save lists using the powerful Lists feature
Analyze and download your search results
Share patent search results with your clients

New to Patents? Find out more from CambridgeIP ®

US7037716: Packaging systems for human recombinant adenovirus to be used in gene therapy

Filing Information

Inventor(s)	Ronald Vogels · Abraham Bout ·
Assignee(s)	Crucell Holland B.V. · View assignee updates
Attorney/Agent(s)	TraskBritt ·
Primary Examiner	David Guzo ·
Application Number	US10396548
Filing date	03/25/2003
Issue date	05/02/2006
Prior Publication Data	US20050074885 - 04/07/2005
Predicted expiration date	12/29/2018
Patent term adjustment	249
U.S. Classifications	435/320.1 · 536/237.2 · 536/241 · 536/231 ·
International Classifications	C12N1500 ·
Kind Code	B2
Related U.S. Application Data	CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation of application Ser. No. 09/900,062, filed Jul. 6, 2001, now abandoned, which was a divisional of application Ser. No. 09/065,752, filed Apr. 24, 1998, now U.S. Pat. No. 6,670,188, issued Dec. 30, 2003.

Abstract

The invention provides improved methods and products based on adenoviral materials which can advantageously be used in gene therapy. In one aspect, an adenoviral vector is provided having no overlap with a suitable packaging cell line. The suitable packaging cell line is another aspect. The combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. Another aspect embodies an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Furthermore, a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, all of which have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system.

Independent Claims | See all claims (2)

1. A recombinant adenovirus wherein the E3-gp19K coding region is replaced by a transgene, wherein any remaining E3 coding regions are intact, which transgene does not comprise a heterologous promoter and which transgene is under transcriptional control of the adenovirus E3 promoter.
2. A plasmid comprising an adenovirus E3 region wherein the E3-gp19K coding region is replaced by a transgene, wherein the remaining E3 coding regions are intact, which transgene does not comprise a heterologous promoter and which transgene is under transcriptional control of the adenovirus E3 promoter.

References Cited

U.S. Patent Documents

Document Number	Assignees	Inventors	Issue/Pub Date
US4405712	The United States of America as represented by the Department of Health and Human Services	Vande Woude et al.	Sep 1983
US4497796	The Regents of the University of California	Salser et al.	Feb 1985
US4727028	Eli Lilly and Company	Santerre et al.	Feb 1988
US4740463	Massachusetts Institute of Technology	Weinberg et al.	Apr 1988
US5190931	The Research Foundation of State University of New York	Inouye	Mar 1993
US5208149	The Research Foundation of State University of New York	Inouye	May 1993
US5378618	E. I. Du Pont de Nemours and Company	Sternberg et al.	Jan 1995
US5518913	National Research Council of Canada	Massie et al.	May 1996
US5545522		Van Gelder et al.	Aug 1996
US5652224	The Trustees of the University of Pennsylvania	Wilson et al.	Jul 1997
US5670488	Genzyme Corporation	Gregory et al.	Sep 1997
US5707618	Genzyme Corporation	Armentano et al.	Jan 1998
US5753500	The Trustees of Princeton University	Shenk et al.	May 1998
US5837511	Cornell Research Foundation, Inc.	Falck-Pedersen et al.	Nov 1998
US5922576	The John Hopkins University	He et al.	Jul 1999
US5935935	Genetic Therapy, Inc.	Connelly et al.	Aug 1999
US5994106	GenVec, Inc.	Kovesdi et al.	Nov 1999
US5994128	IntroGene B.V.	Fallaux et al.	Nov 1999
US6033908	b.v. IntroGene	Bout et al.	Mar 2000
US6040174	Transgene S.A.	Imler et al.	Mar 2000
US6238893	Introgene B.V.	Hoeben et al.	May 2001
US6306652	IntroGene B.V.	Fallaux et al.	Oct 2001
US6413776	Galapagos Geonomics N.V.	Vogels et al.	Jul 2002
US6602706	Introgene B.V.	Fallaux et al.	Aug 2003

Foreign Patent Documents

Document Number	Assignees	Issue/Pub Date
AUA2853395		Mar 1996
CA2053187	CANADA MAJESTY IN RIGHT OF	Apr 1993
CA2117668	SUMITOMO PHARMA	Sep 1995
EP95201611.1		Jun 1995
EP95201728.3		Jun 1995
FR2707664	CENTRE NAT RECH SCIENT	Jan 1995
WO199102804*		Mar 1991
WO199412649		Jun 1994
WO199423582		Oct 1994
WO199426914		Nov 1994
WO199428152		Dec 1994
WO199500655		Jan 1995
WO199502697		Jan 1995
WO199527071		Oct 1995
WO199616676		Jun 1996
WO199618418		Jun 1996
WO199633280		Oct 1996
WO199640955		Dec 1996
WO199700326		Jan 1997
WO199700947		Jan 1997
WO199704119		Feb 1997
WO199705255		Feb 1997

* cited by examiner

Other Publications

Amalfitano et al., “Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors,” Proc. Natl. Acad. Sci. USA, 93:3352-3356, Apr. 1996.

Amalfitano et al., “Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy,” Gene Therapy, 4:258-263,1997.

Armentano et al., “Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion,” Human Gene Therapy, 6:1343-1353, Oct. 1995.

Berkner, Expression of Heterologous Sequences in Adenoviral Vectors, Current Topics in Microbiology and Immunology, vol. 158, Springer-Verlag Berlin Heidelberg 1992.

Blaese et al., Vectors in Cancer therapy: how will they deliver?, Cancer Gene Therapy, vol. 2, No. 4, 1995, pp. 291-297.

Bout et al., “In vivo adenovirus-mediated transfer of human CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity and safety,” Gene Therapy 1, pp. 385-394, 1994.

Bout et al., “Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium,” Human Gene Therapy, 5:3-10, 1994.

Brough et al., “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4,” Journal of Virology, 70(9):6497-6501, Sep. 1996.

Brough et al., Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4; Abstract Book CSH Conference on Gene Therapy, 42, 1996.

Brough et al., “Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein,” Virology, 190:624-634, 1992.

Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5,” Journal of Virology, 69(11):6627-6633, Nov. 1995.

Fallaux et al., “Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors,” Human Gene Therapy, 7:215-222, 1996.

Fisher et al., “Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis,” Virology, 217:11-22, 1996.

Gao et al., “Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy,” Journal of Virology, 70(12):8934-8943, Dec. 1996.

Gorziglia et al., “Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy,” Journal of Virology, 70(6):4173-4178, Jun. 1996.

Haddada et al., “Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice,” Human Gene Therapy, 4:703-711, 1993.

Hardy et al., “Construction of Adenovirus Vectors through Cre-Iox Recombination,” Journal of Virology, 71(3):1842-1849, Mar. 1997.

Hehir et al., “Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications to Prevent Their Occurrence,” Journal of Virology, 70(12):8459-8467, Dec. 1996.

Imler et al., “Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors,” Gene Therapy, 3:75-84, 1996.

Kornberg, Arthur, “DNA Replication,” W.H.Freeman and Company, San Francisco, 4 pages (double sided).

Krougliak et al., “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants,” Human Gene Therapy, 6:1575-1586, Dec. 1995.

Lieber et al., “Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo,” Journal of Virology, 70:8944-8960, Dec. 1996.

Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” The Protein Folding Problem and Tertiary Structure Prediction, 5 pages.

Sabatie et al., “Process Development for the Production of Second Generation Adenovirus Vectors for Gene Transfer in Clinical Protocols,” Abstract Book 14th Meeting on Animal Cell Technolgoy, BI3, 1996.

Schaack et al., “Adenivorus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines,” Journal of Virology, 69(7):4079-4085, Jul. 1995.

Stratford-Perricaudet et al., Gene transfer into animals: the promise of adenovirus, Human Gene Transfer, 1991, vol. 219, pp. 51-61.

Vanhaesebroeck et al., “Modulation of Cellular Susceptibility to the Cytotoxic/Cytostatic Action of Tumor Necrosis Factor by Adenovirus E1 Gene Expression Is Cell Type-Dependent,” Virology, 176(2), pp. 362-368, Jun. 1990.

Vincent et al., “Herpes Simplex Virus Thymidine Kinase Gene Therapy for Rat Malignant Brain Tumors,” Human Gene Therapy 7:197-205, Jan. 20, 1996.

Vincent et al., “Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene,” J. Neurosurg., vol. 85, pp. 648-654, 1996.

Wang et al., “A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions,” Gene Therapy, 2:775-783, 1995.

Yeh et al., “Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit”, Journal of Virology, 70(1):559-565, Jan. 1996.

Zhou et al., “Development of a Complementing Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted,” Journal of Virology, 70(1):7030-7038, Oct. 1996.

McKinnon et al., Tn5 mutagenesis of the transforming genes of human adenovirus type 5. Gene, 1982, pp. 33-42, vol. 19.